Increased Leishmania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E2 synthesis

被引:47
作者
Barreto-de-Souza, Victor
Pacheco, Graziela J.
Silva, Adriana R.
Castro-Faria-Neto, Hugo C.
Bozza, Patricia T.
Saraiva, Elvira M.
Bou-Habib, Dumith Chequer
机构
[1] Fiocruz MS, Inst Oswaldo Cruz, Dept Immunol, Clin Immunol Lab, BR-21045900 Rio De Janeiro, Brazil
[2] Fiocruz MS, Inst Oswaldo Cruz, Lab Immunofarmacol, Dept Fisiol & Farmacodinam, BR-21045900 Rio De Janeiro, Brazil
[3] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo Goes, Dept Immunol, Lab Imunobiol Leishmanioses, Rio De Janeiro, Brazil
基金
美国国家卫生研究院;
关键词
D O I
10.1086/506618
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Protozoan parasites of the genus Leishmania frequently occur as opportunistic pathogens in human immunodeficiency virus type 1 (HIV-1)-infected individuals, but the mechanisms underlying protozoan growth in this context are poorly understood. Here, we demonstrate that the HIV-1 Tat protein drives Leishmania replication in primary human macrophages. We found that Leishmania growth doubled in HIV-1-infected macrophages and that anti-Tat antibodies reduced the exacerbated protozoan replication by 70%. Recombinant Tat increased Leishmania replication and overrode the leishmanicidal effect induced by interferon-gamma, allowing Leishmania replication even in the presence of this cytokine. Tat induced cyclooxygenase (COX)-2 expression and prostaglandin E-2 (PGE(2)) synthesis, and a COX-2 inhibitor abolished the Tat-mediated augmentation of Leishmania replication. Moreover, PGE(2) increased Leishmania growth, which was abrogated by anti - transforming growth factor (TGF)-beta 1 monoclonal antibodies. Neutralization of TGF-beta 1 reduced parasite growth in Leishmania-infected macrophages exposed to Tat by 50%. Our findings suggest that Tat generates a milieu permissive to Leishmania growth in individuals infected with HIV-1.
引用
收藏
页码:846 / 854
页数:9
相关论文
共 43 条
[1]   Macrophages and HIV infection:: therapeutical approaches toward this strategic virus reservoir [J].
Aquaro, S ;
Caliò, R ;
Balzarini, J ;
Bellocchi, MC ;
Garaci, E ;
Perno, CF .
ANTIVIRAL RESEARCH, 2002, 55 (02) :209-225
[2]   Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: Implication of protein kinase C-dependent pathway [J].
Badou, A ;
Bennasser, Y ;
Moreau, M ;
Leclerc, C ;
Benkirane, M ;
Bahraoui, E .
JOURNAL OF VIROLOGY, 2000, 74 (22) :10551-10562
[3]   TRANSFORMING GROWTH-FACTOR-BETA IN LEISHMANIAL INFECTION - A PARASITE ESCAPE MECHANISM [J].
BARRALNETTO, M ;
BARRAL, A ;
BROWNELL, CE ;
SKEIKY, YAW ;
ELLINGSWORTH, LR ;
TWARDZIK, DR ;
REED, SG .
SCIENCE, 1992, 257 (5069) :545-548
[4]   The human immunodeficiency virus type 1 regulatory protein Tat inhibits interferon-induced iNos activity in a murine macrophage cell line [J].
Barton, CH ;
Biggs, TE ;
Mee, TR ;
Mann, DA .
JOURNAL OF GENERAL VIROLOGY, 1996, 77 :1643-1647
[5]   Nitric oxide and the immune response [J].
Bogdan, C .
NATURE IMMUNOLOGY, 2001, 2 (10) :907-916
[6]   HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region [J].
Chang, HC ;
Samaniego, F ;
Nair, BC ;
Buonaguro, L ;
Ensoli, B .
AIDS, 1997, 11 (12) :1421-1431
[7]   Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana [J].
Couppié, P ;
Clyti, E ;
Sobesky, M ;
Bissuel, F ;
Del Giudice, P ;
Sainte-Marie, D ;
Dedet, JP ;
Carme, B ;
Pradinaud, R .
BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 (06) :1165-1171
[8]   Atypical mucocutaneous leishmaniasis caused by Leishmania braziliensis in an acquired immunodeficiency syndrome patient:: T-cell responses and remission of lesions associated with antigen immunotherapy [J].
Da-Cruz, AM ;
Filgueiras, DV ;
Coutinho, Z ;
Mayrink, W ;
Grimaldi, G ;
De Luca, PM ;
Mendonça, SCF ;
Coutinho, SG .
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 1999, 94 (04) :537-542
[9]   Practical guide for the treatment of leishmaniasis [J].
Davidson, RN .
DRUGS, 1998, 56 (06) :1009-1018
[10]   Leishmania/HIV co-infections:: epidemiology in Europe [J].
Desjeux, P ;
Alvar, J .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 2003, 97 :3-15